Investors
Corporate Profile
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.
Presentations
DateTitle
07/10/17
Dimension Therapeutics Corporate Presentation July 2017
Download Documentation
Stock
DMTX (Common Stock) $1.30 + 0.08 (5.69%)
High $1.30
Events
Dimension Therapeutics Q4 2016 Earnings and Corporate Update Conference Call
03/09/17 8:30 a.m. ET
E-mail Alerts
Sign up to receive
E-mail Alerts
 
News
August 08, 2017
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A programs expected in early 2018 CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today reported financial results for t[...]  Read More /
July 24, 2017
Dimension Therapeutics Announces Management Change
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Jean Franchi, Chief Financial Officer, has resigned in order to pursue other opportunities, effective July 28, 2017.  "The Board and I wish to express our thanks to Jean for her contributions and service to Dimension's leadership team[...]  Read More /
June 27, 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in 2018 Operating expenses reduced and cash runway extended CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, t[...]  Read More /
Data provided by Nasdaq. Minimum 15 minutes delayed.